Search tips
Search criteria

Results 1-11 (11)

Clipboard (0)
Year of Publication
1.  How safe is paracetamol? 
Archives of Disease in Childhood  2015;100(1):73-74.
PMCID: PMC4283624  PMID: 25512959
Pharmacology; Pain; General Paediatrics
2.  Safety of new medicines in young children 
Archives of Disease in Childhood  2011;96(9):872-873.
PMCID: PMC3198508  PMID: 21836178
3.  Rational prescribing is important in all settings 
PMCID: PMC3756449  PMID: 23852999
General Paediatrics; Pharmacology
4.  Inter-individual variation in midazolam clearance in children 
Archives of Disease in Childhood  2014;100(1):95-100.
To determine the extent of inter-individual variation in clearance of midazolam in children and establish which factors are responsible for this variation.
A systematic literature review was performed to identify papers describing the clearance of midazolam in children. The following databases were searched: Medline, Embase, International Pharmaceutical Abstracts, CINAHL and Cochrane Library. From the papers, the range in plasma clearance and the coefficient of variation (CV) in plasma clearance were determined.
25 articles were identified. Only 13 studies gave the full range of clearance values for individual patients. The CV was greater in critically ill patients (18%–170%) than non-critically ill patients (13%–54%). Inter-individual variation was a major problem in all age groups of critically ill patients. The CV was 72%–106% in preterm neonates, 18%–73% in term neonates, 31%–130% in infants, 21%–170% in children and 47%–150% in adolescents. The mean clearance was higher in children (1.1–16.7 mL/min/kg) than in neonates (0.78–2.5 mL/min/kg).
Large inter-individual variation was seen in midazolam clearance values in critically ill neonates, infants, children and adolescents.
PMCID: PMC4283666  PMID: 25281734
Pharmacology; General Paediatrics
5.  Setting the research agenda for women and children: the role of Health Technology Assessment 
Archives of Disease in Childhood  2013;98(8):574-575.
PMCID: PMC3717783  PMID: 23749947
Epidemiology; Evidence Based Medicine
6.  Why children do not receive treatment 
Archives of Disease in Childhood  2014;99(7):605-606.
PMCID: PMC4078697  PMID: 24748640
Children's Rights; General Paediatrics; Pharmacology
7.  Paediatric clinical pharmacology in the UK 
Archives of Disease in Childhood  2014;99(12):1143-1146.
Paediatric clinical pharmacology is the scientific study of medicines in children and is a relatively new subspecialty in paediatrics in the UK. Training encompasses both the study of the effectiveness of drugs in children (clinical trials) and aspects of drug toxicity (pharmacovigilance). Ethical issues in relation to clinical trials and also studies of the pharmacokinetics and drug metabolism in children are crucial. Paediatric patients require formulations that young children in particular are able to take. The scientific evidence generated from clinical trials, pharmacokinetic studies and studies of drug toxicity all need to be applied in order to ensure that medicines are used rationally in children.
PMCID: PMC4251165  PMID: 25202131
Pharmacology; Toxicology; Evidence Based Medicine
8.  Child health in Central America and the Caribbean 
Archives of Disease in Childhood  2015;100(Suppl 1):S70-S71.
PMCID: PMC4316849  PMID: 25613976
Children's Rights; Health Service
9.  Hurricanes and child health: lessons from Cuba 
Archives of Disease in Childhood  2010;96(4):328-329.
PMCID: PMC3056292  PMID: 20861403
10.  Armed conflict and child health 
Armed conflict has a major impact on child health throughout the world. One in six children worldwide lives in an area of armed conflict and civilians are more likely to die than soldiers as a result of the conflict. In stark contrast to the effect on children, the international arms trade results in huge profits for the large corporations involved in producing arms, weapons and munitions. Armed conflict is not inevitable but is an important health issue that should be prevented.
PMCID: PMC3237260  PMID: 21393303
11.  Ciprofloxacin safety in paediatrics: a systematic review 
Archives of Disease in Childhood  2011;96(9):874-880.
To determine the safety of ciprofloxacin in paediatric patients in relation to arthropathy, any other adverse events (AEs) and drug interactions.
A systematic search of MEDLINE, EMBASE, CINAHL, CENTRAL and bibliographies of relevant articles was carried out for all published articles, regardless of design, that involved the use of ciprofloxacin in any paediatric age group ≤17 years. Only articles that reported on safety were included.
105 articles met the inclusion criteria and involved 16 184 paediatric patients. There were 1065 reported AEs (risk 7%, 95% CI 3.2% to 14.0%). The most frequent AEs were musculoskeletal AEs, abnormal liver function tests, nausea, changes in white blood cell counts and vomiting. There were six drug interactions (with aminophylline (4) and methotrexate (2)). The only drug related death occurred in a neonate who had an anaphylactic reaction. 258 musculoskeletal events occurred in 232 paediatric patients (risk 1.6%, 95% CI 0.9% to 2.6%). Arthralgia accounted for 50% of these. The age of occurrence of arthropathy ranged from 7 months to 17 years (median 10 years). All cases of arthropathy resolved or improved with management. One prospective controlled study estimated the risk of arthropathy as 9.3 (OR 95% CI 1.2 to 195). Pooled safety data of controlled trials in this review estimated the risk of arthropathy as 1.57 (OR 95% CI 1.26 to 1.97).
Musculoskeletal AEs occur due to ciprofloxacin use. However, these musculoskeletal events are reversible with management. It is recommended that further prospective controlled studies should be carried out to evaluate the safety of ciprofloxacin, with particular focus on the risk of arthropathy.
PMCID: PMC3155117  PMID: 21785119

Results 1-11 (11)